PLx Pharma (PLXP)

PLx Pharma Inc. is a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract. PLx believes this has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach erosions and ulcers associated with aspirin and ibuprofen, and potentially other drugs.

Company profile

Ticker

PLXP

Exchange

NASDAQ

Website

plxpharma.com

CEO

Natasha Giordano

Incorporated

Delaware

Location

New Jersey

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Lilly(Eli) & Co • Bristol-Myers Squibb • Viatris • Abbvie ...

Former names

Dipexium Pharmaceuticals, Inc., Dipexium Pharmaceuticals, LLC

SEC CIK

0001497504

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

PLx Opco Inc. ...

PLXP stock data

1M 1Y 5Y

News

From Benzinga Pro

Why Energy Stocks Traded Higher; Here Are 61 Biggest Movers From Yesterday

26 Jul 22

Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) jumped 150.4% to close at $1.59 on Monday after declining 8% on Friday.

This Technology Stock Surged 235%; Here Are 77 Biggest Movers From Friday

25 Jul 22

Gainers

12 Health Care Stocks Moving In Wednesday's Intraday Session

20 Jul 22

Stocks That Hit 52-Week Lows On Monday

13 Jun 22

Raymond James Maintains Outperform on PLx Pharma, Lowers Price Target to $10

16 May 22

Press releases

From Benzinga Pro

PLx Pharma Inc. to Report Second Quarter 2022 Financial Results August 12, 2022, and Provide Business Update

27 Jul 22

SPARTA, N.J., July 27, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company") is a commercial-stage drug delivery platform technology company focused on its clinically-validated and

PLx Pharma Inc. Showcases VAZALORE at The Annual Meeting of The Society for Cardiovascular Angiography and Interventions

20 May 22

SPARTA, N. J., May 20, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and

PLx Pharma Inc. Reports First Quarter 2022 Results and Provides Business Update

13 May 22

BUILDING A SOLID BASE OF VAZALORE® USERS Total Net Sales of $2.1 Million in the First Quarter of 2022, an Increase of Approximately 31% from Fourth Quarter of 2021GAAP Net Loss of ($0.39) Per Diluted Share in the

Analyst ratings and price targets

Last 3 months

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

13 May 22

8 Aug 22

31 Dec 22

Financial summary

Financial statements Chart PLXP financial data

Quarter (USD)	Mar 22	Dec 21	Sep 21	Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	52.5M	52.5M	52.5M	52.5M	52.5M	52.5M
Cash burn (monthly)	5.63M	2.66M	6.07M	6.43M	5.63M	3.73M
Cash used (since last report)	24.18M	11.42M	26.04M	27.62M	24.18M	16M
Cash remaining	28.32M	41.08M	26.46M	24.88M	28.32M	36.5M
Runway (months of cash)	5.0	15.4	4.4	3.9	5.0	9.8

Beta Read what these cash burn values mean

Financial data from PLx Pharma earnings reports.

Recent insider trades

PLXP insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
15 Mar 22	O'Connor Rita M	Common Stock	Buy	Acquire P	No	No	3.6546	3,700	13.52K	26,670
15 Mar 22	O'Connor Rita M	Common Stock	Buy	Acquire P	No	No	3.66	10,000	36.6K	22,970
15 Mar 22	Giordano Natasha	Common Stock	Buy	Acquire P	No	No	3.6529	4,100	14.98K	5,186
22 Feb 22	Balkema Gary S.	Stock Option Common Stock	Grant	Acquire A	No	No	4.99	20,000	99.8K	20,000
22 Feb 22	Calhoun Kirk K	Stock Option Common Stock	Grant	Acquire A	No	No	4.99	20,000	99.8K	20,000
22 Feb 22	Casale Robert	Stock Option Common Stock	Grant	Acquire A	No	No	4.99	20,000	99.8K	20,000

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

PLXP institutional ownership history Ownership history

51.6% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	52	59	-11.9%
Opened positions	10	12	-16.7%
Closed positions	17	17	–
Increased positions	11	22	-50.0%
Reduced positions	19	12	+58.3%

13F shares	Current	Prev Q	Change
Total value	133.67M	119.72M	+11.7%
Total shares	14.21M	14.94M	-4.9%
Total puts	156.2K	179.2K	-12.8%
Total calls	149.5K	384.3K	-61.1%
Total put/call ratio	1.0	0.5	+124.1%

Largest owners	Shares	Value	Change
White Rock Capital Management	2.81M	$22.52M	0.0%
Level One Partners	2.77M	$22.21M	0.0%
MSD Partners	1.88M	$7.58M	0.0%
Park West Asset Management	1.47M	$5.95M	0.0%
Vanguard	1.1M	$4.45M	-3.7%
MS Morgan Stanley	854.74K	$3.45M	-0.4%
GW&K Investment Management	428.17K	$1.73M	-1.1%
BLK Blackrock	406.98K	$1.64M	-0.4%
Two Sigma Advisers	393.5K	$1.59M	-15.8%
Two Sigma Investments	338.83K	$1.37M	-20.3%

Largest transactions	Shares	Bought/sold	Change
Friess Associates	0	-278.07K	EXIT
Millennium Management	0	-143.46K	EXIT
D. E. Shaw & Co.	111.63K	+111.63K	NEW
First Republic Investment Management	179.23K	-104.29K	-36.8%
Shay Capital	88.62K	+88.62K	NEW
Two Sigma Investments	338.83K	-86.31K	-20.3%
Two Sigma Advisers	393.5K	-73.7K	-15.8%
Raymond James & Associates	0	-66.56K	EXIT
Cubist Systematic Strategies	12.27K	-53.34K	-81.3%
MBL Wealth	52K	+52K	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Pfizer • Antibe Therapeutics • Aralez Pharmaceuticals

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: batch, bottle, broader, capacity, category, count, Dipexium, discover, expanding, extend, flow, frozen, grocery, lining, list, longer, notwithstanding, NSAID, optimization, percentage, preclinical, proportionally, screening, seek, store, Topic, variety, warehouse

Removed: account, accredited, affordable, agreement, allocate, annually, annum, approach, arising, arrangement, authority, bank, banking, book, borrowed, calculating, charge, Codification, commencement, compounded, computation, context, continuing, Corporation, deficit, Deposit, depreciable, dividend, employee, enacted, enactment, examination, exposure, face, feature, February, federally, fee, final, floating, foreign, franchise, fulfill, fully, gain, general, greater, housing, identified, inception, initially, institution, insured, intraperiod, investing, investment, January, July, knowledge, largest, liquid, liquidation, making, mitigate, mitigated, monthly, NDA, occurred, October, original, originally, ownership, partially, performed, placement, preference, presence, prime, qualified, qualitative, realized, reborrowed, recovered, relevant, removing, Rent, represent, requirement, requiring, resulting, review, Security, separate, settled, Silicon, simplify, simplifying, step, sublease, subsequently, supplemental, sustained, symbol, tax, taxable, temporary, thereunder, TM, unit, unpaid, Valley, York

From filing 10-Q 2022 Q1

Financial reports

View all

Annual report (amended)

29 Apr 22

10-K